Original Contributions |
From the Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.
Correspondence to Dr Samuel E. George, Box 3060, Division of Cardiology, Duke University Medical Center, Durham, NC 27710. E-mail georg004{at}mc.duke.edu
| Abstract |
|---|
|
|
|---|
days) in 52 New Zealand White
rabbits undergoing gene transfer (ß-galactosidase or empty vector) or
sham procedures to both carotid arteries. After gene transfer, arteries
were either left in vivo for 1 hour to 3 days (in vivo arteries) or
were excised immediately after gene transfer and cultured (ex vivo
arteries). Within 1 hour, in vivo arteries receiving infectious titers
of
4x109 plaque-forming units (pfu)/mL showed
endothelial activation, with an acute inflammatory
infiltrate developing by 6 hours. Ex vivo arteries showed
endothelial activation but no inflammatory infiltrate.
There were also significant differences in transgene expression between
in vivo and ex vivo arteries. Ex vivo arteries showed titer-dependent
increases in ß-galactosidase expression through 2x1010
pfu/mL, whereas in in vivo arteries, titers above 4x109
pfu/mL merely increased acute inflammatory response, without increasing
transgene expression. In vivo arteries showed significant time- and
titer-dependent impairment in endothelium-dependent
relaxation, with no effect on contraction or nitroprusside-induced
relaxation. Interestingly, however, if rabbits were made neutropenic
with vinblastine, their arteries maintained full
endothelium-dependent relaxation, even after very high
titer vascular infection (up to 1x1011 pfu/mL). These
findings show that recombinant adenovirus triggers an early
inflammatory response, and it is the inflammatory response that in turn
causes functional endothelial injury. This occurs at
much lower titers than previously appreciated (though the precise
threshold will undoubtedly vary between laboratories). However, titers
below the inflammatory threshold produce excellent transgene expression
without inflammation or vascular injury.
Key Words: adenovirus gene transfer endothelium inflammation neutrophil
| Introduction |
|---|
|
|
|---|
2
weeks,6 and an adenovirus-induced chronic
inflammatory response produces significant endothelial
injury and neointimal proliferation that confound data
interpretation and counter any potential therapeutic
effect.7 These untoward effects are largely
attributable to a virus-induced host immune response.
Acute vascular effects of adenoviral gene transferthose occurring
within 3 days of gene transferhave also been described but are less
well characterized: (1) in normal rat arteries, complete
endothelial denudation after high-titer
(2x1011 pfu/mL) gene transfer but no apparent
injury at lower titers (
1011
pfu/mL),8 (2) in balloon-injured rat arteries, an
acute medial inflammatory infiltrate and smooth muscle cell loss in
arteries receiving 1011
pfu/mL,9 and (3) in normal rabbit carotid
arteries, a medial inflammatory infiltrate, an impaired response to
contractile agonists, and complete loss of
endothelium-dependent vasodilation after moderately
high-titer (4x1010 pfu/mL) gene
transfer.10
These observations have led to 2 general hypotheses about adenovirus-induced acute injury. One is that the adenovirus itself is directly toxic to the vessel ("direct viral toxicity"),8 11 a view supported by the cytotoxic effects of high-multiplicity recombinant adenovirus infections in cell culture and the known in vitro cytotoxicity of some adenoviral proteins, such as the penton base.12 13 The second is that the observed injury is a host-mediated effect, largely secondary to acute inflammatory cell infiltrate, that develops after high-titer gene transfer.14 A better understanding of adenovirus-induced acute effects and the cellular mechanisms through which they are produced may be particularly important for vascular gene transfer, since these effects may have an untoward impact on transgene expression8 and the subsequent development of neointimal proliferation.7
Accordingly, we undertook the present study to define more thoroughly the acute vascular effects of adenovirus and to answer the following general questions about adenoviral gene transfer in normal rabbit arteries: (1) What is the extent of acute vascular inflammation, and what is its time course and titer dependence? (2) What is the impact of acute vascular inflammation on transgene expression? (3) To what extent does adenoviral gene transfer functionally impair the vessel, and if functional impairment is present, what is its time course and titer dependence? (4) What is the relative contribution of "direct viral toxicity" and host-mediated inflammatory effects to the observed functional deficits?
The present study shows that a titer-dependent acute inflammatory response that significantly limits transgene expression and endothelial vasomotor function develops within hours of vascular gene transfer. Moreover, our data suggest that the host response, rather than direct viral toxic effects, is largely responsible for the observed endothelial injury.
| Materials and Methods |
|---|
|
|
|---|
Preparation of Adenovirus Vector
We generated a recombinant adenovirus, Ad.ß-Gal, derived from
the in340 mutant strain of Ad5, containing a nuclear-targeted ß-Gal
transgene and expression cassette in the E1 region, as previously
described.15 Virus was purified from infected 293
cells by lysis in virus storage buffer (20 mmol/L Tris [pH 7.4],
150 mmol/L NaCl, 5 mmol/L KCl, and 1 mmol/L
MgCl2), followed by
ultracentrifugation of the lysate on a 1.3 to 1.4 g/mL
cesium chloride step gradient at 100 000g for 2.5 hours at
4°C. Virus was harvested, and residual cellular RNA was removed by
incubation with RNase A (100 µg/mL, Sigma Chemical Co) for 30 minutes
at room temperature. Pooled virus was ultracentrifuged
overnight on a second cesium chloride gradient at 4°C. Pure virus was
harvested and desalted by serial gel filtration on Sepharose CL-6B spin
columns (Pharmacia) in virus storage buffer. Gel-filtered virus was
diluted 1:1 with 80% normal rabbit serum/20% glycerol (virus storage
medium) and immediately frozen in aliquots. Viral concentration was
initially estimated spectrophotometrically by absorbance at 260 nm, and
infectious titer of all viral stocks was determined by at least 3
independent plaque assays on 293 cells using standard techniques
(1-hour infection at 37°C, without
rocking).16
Screening of Preparations to Exclude Wild-Type Adenovirus
Contamination
Wild-type contamination was shown to be <1 in
107 by PCR analysis, using primers
designed to amplify a 560-bp product corresponding to Ad5 base
pairs 690 to 1250 (sense primer, 5' ACGAACTGTATGATTTAGACG 3' [Ad5 base
pairs 690 to 711]; antisense primer, 5' AGGCTCAGGTTCAGACACAGG 3' [Ad5
base pairs 1250 to 1229]). As a positive control, serial 10-fold
dilutions of Ad5 adenovirus DNA, ranging from 1 ng to 1 fg
(106 to 1 copy of the in340 adenovirus genome)
were used as template in the PCR. A single copy of Ad5 DNA produced a
clearly visible 560-bp band. No recombinant preparations produced a
positive PCR result, unless >107 copies of the
recombinant adenovirus DNA were present in the PCR. In addition, no
recombinant preparation produced cell death on cultured human vascular
smooth muscle cells, despite high multiplicity of infection levels
(
100 pfu/cell) and observation periods of up to 10 days. In contrast,
Ad5 preparations rapidly induced cell death in human vascular smooth
muscle cells (within 3 days at a multiplicity of infection of 1).
Carotid Artery Gene Transfer
Rabbits underwent gene transfer to both carotid arteries in an
identical manner. High-titer viral stock, maintained on dry ice until
immediately before use, was thawed and diluted with DMEM/virus storage
medium to ensure equal composition of virus solutions at different
viral titers. Mock infections were carried out using DMEM/virus storage
medium alone. At surgery, the right and left carotid arteries were
carefully exposed through a midline neck incision. Heparin (700 IU IV)
was administered, and gene transfer was performed by isolating the
exposed vessel segment between microvascular clamps. A 24-gauge
polytetrafluoroethylene (Teflon) cannula
was inserted through a proximal arteriotomy, and the lumen of the
vessel was cleared of blood by gentle flushing with DMEM. Approximately
200 µL of virus solution was instilled into the vessel lumen and
incubated for 20 minutes. The arteriotomy was then repaired using 10/0
nylon sutures.
Induction of Neutropenia With Vinblastine
To induce neutropenia, animals received intravenous
vinblastine according to previous protocols.17 18
Two doses of 1.5 mg vinblastine were given: 3 days before and, again, 1
day before surgery and gene transfer. A peripheral blood
sample was taken immediately before each dose, on the day of surgery,
and at the harvest of the vessels to ensure that profound neutropenia
had been induced by the time of surgery and had been maintained
throughout the experimental period. Peripheral blood counts
were determined by Coulter counter, and absolute counts of neutrophils
and lymphocytes were also determined by manual counting of blood
smears. During vinblastine treatment, animals received a single daily
dose of enrofloxacin (Baytril, 15 mg, Miles Inc) subcutaneously.
Vessel Harvesting and Analysis
Vessels were harvested at time points from 1 hour to 72 hours
after surgery. Animals were anesthetized and heparinized (700
IU IV), and the carotid arteries were dissected free. Animals were
killed with an intravenous overdose of pentobarbital
sodium, and vessels were excised and washed in PBS. At the same time,
ex vivo vessel rings were removed from the incubator and processed in
parallel. Segments from all vessels were immediately frozen at -80°C
for protein extraction or were rapidly processed for frozen sections
and immunohistochemistry.
ß-Gal and total protein concentration was quantified in frozen vessel segments using an ELISA kit (5 Prime-3 Prime) and a Bradford protein assay. ß-Gal protein quantity was determined as nanograms ß-Gal per milligram of vessel protein.
Immunohistochemistry and Image Analysis
Vessel segments were briefly equilibrated in 30% sucrose in PBS
at 4°C, embedded in optimal cutting temperature compound (Miles
Scientific), frozen in liquid nitrogen, and sectioned (6 µm)
onto silane-coated glass microscope slides. Vessel sections were
thawed, dried, and then stained for ß-Gal by incubation at room
temperature in X-Gal solution for 4 hours (20 mmol/L Tris [pH
7.4], 150 mmol/L NaCl, 5 mmol/L potassium ferricyanide,
5 mmol/L potassium ferrocyanide, and 2 mmol/L
MgCl2 containing 0.5 mg/mL X-Gal).
Immunohistochemistry to identify CD18+
leukocytes, T lymphocytes, or macrophages was performed using
primary antibodies directed against rabbit CD18
(Serotec),19 rabbit CD43 (T11/135,
Serotec),7 or rabbit RAM 11
(Dako),19 respectively. VCAM-1 and ICAM-1 were
identified using monoclonal antibodies raised against rabbit VCAM-1 and
ICAM-120 (a generous gift of Dr M. Cybulsky,
University of Toronto). Immunostaining of
smooth muscle cells (HHF 35, Dako) and endothelial
cells (antivon Willebrand factor, Atlantic Antibodies) was
also performed. Briefly, frozen sections were fixed for 10 minutes in
cold acetone and then equilibrated in PBS. Blocking solution (1.5%
horse serum in PBS) was applied for 1 hour at room temperature.
Antibodies were diluted in blocking solution at concentrations
determined in preliminary experiments and were applied to tissue
sections for 1 hour. This was followed by sequential incubation with
biotinylated anti-mouse IgG (except for von Willebrand factor
staining) and ABC reagent (Vectastain ABC kit, Vector Laboratories,
Inc). Immune complexes were localized using the chromogenic
alkaline phosphatase substrate Vector Red (Vector Laboratories, Inc).
The sections were lightly counterstained with hematoxylin, dehydrated,
and mounted with Permount (Fisher Scientific). In all experiments an
adjacent section was incubated with an irrelevant murine IgG monoclonal
antibody to serve as a negative control. Staining intensity was
quantified using an image analysis system (Olympus IX70
inverted microscope, Optronics DEI-750 image capturing hardware,
PowerTowerPro 180 CPU). Images were captured using Adobe Premiere and
quantified using NIH Image 1.61 software.
Endothelial inflammatory cell infiltration was assessed by counting the total number of CD18+ or CD43+ leukocytes on the luminal surface of arterial cross sections. Counting was performed at x200 magnification, in a blinded fashion, using a pointing device and a manual counter. The mean number of luminal inflammatory cells was calculated from counting multiple vessel cross sections (range, 4 to 20; median, 8 sections/vessel).
Vasomotor Studies
Freshly harvested vessels were cleaned of fat and connective
tissues, cut into helical strips, and mounted in 30-mL organ baths
containing Krebs-Henseleit buffer (mmol/L: NaCl 120, KCl 4.7,
CaCl2 2.5, MgSO4 1.2,
KH2PO4,
NaHCO3, and glucose 5.5 mmol/L, pH 7.4)
maintained at 37°C and oxygenated with 95%
O2/5% CO2. Vessels were
equilibrated for 60 minutes, with changes of bathing fluid every 15
minutes. Isometric tension studies were performed using a Grass model
7D polygraph. Optimal resting tension was determined in baseline
studies, and the response to vasoactive drugs was then determined.
Cumulative dose-response curves to PE (10-9 to
10-4 mol/L) were established. The vessels were
then submaximally precontracted with PE (typically
3x10-6 mol/L), and endothelial
function was evaluated by vascular relaxation to ACh
(10-8 to 10-4 mol/L). NO
mediation of ACh responses was confirmed by blocking ACh-induced
relaxation by N-methyl-L-arginine (1
mmol/L), a specific competitive inhibitor of NO synthase.
After they were washed, the vessels were again precontracted, and
endothelium-independent relaxation responses to SNP
(10-8 to 10-4 mol/L) were
determined. Contractile responses were measured from the polygraph
chart and expressed as a percentage of the maximal contraction or, for
relaxations, as a percentage of the precontracted tension. Statistical
significance of the differences between responses was assessed by
ANOVA.
| Results |
|---|
|
|
|---|
A total of 19 carotid artery pairs were studied. They were infected
with titers ranging from 4x108 to
5x1011 pfu/mL (Figure 1
).
|
The in vivo arteries showed a striking plateau in transgene expression. ß-Gal protein was detectable at the lowest titer evaluated and rose to near-maximal levels at a titer of 1.6x109 pfu/mL. However, ß-Gal levels showed no significant increase from 2x109 through 1x1011 pfu/mL, and a further increase in titer (to 5x1011 pfu/mL) significantly reduced ß-Gal expression. In ex vivo arteries, transgene expression was higher than in the paired contralateral in vivo arteries at all titers studied. In addition, expression in ex vivo arteries increased steadily as infecting titers were increased from 1.6x109 to 2x1010 pfu/mL. Thus, the gap between ex vivo and in vivo expression became progressively larger in this titer range (reaching a 6-fold difference at 2x1010 pfu/mL). This suggested that some host factor(s) may be limiting transgene expression in vivo.
Adenovirus-Mediated Gene Transfer Provokes Time- and
Titer-Dependent Endothelial Activation
We examined arteries for evidence of endothelial
activation and acute inflammation after from 1 to 72 hours after
infection with recombinant adenovirus. Cryosections were evaluated by
immunohistochemistry to identify VCAM-1, ICAM-1,
CD18+, and CD43+ leukocytes
(T lymphocytes). CD18+ leukocytes were identified
as PMNs, as they had multilobed nuclei and did not stain with RAM 11,
which would identify CD18+ monocytes.
ICAM-1 was detectable at 6 hours after adenoviral infection in both the
adventitia and endothelium (Figure 2
). ICAM-1 immunostaining
increased through 24 hours and remained at high levels at 72 hours.
VCAM-1 was detectable as early as 1 hour and, like ICAM-1, increased
through 24 hours and remained at high levels at 72 hours. However,
VCAM-1 staining was confined to the endothelium.
Mock-infected arteries showed no endothelial ICAM-1 or
VCAM-1 expression (Figure 2
, bottom panels), nor did arteries infected
with low-titer adenovirus (1.6x109 pfu/mL, not
shown). Thus, high-titer recombinant adenoviral gene transfer induces
endothelial activation very soon after infection.
|
The degree of endothelial activation was also titer
dependent, as judged by immunohistochemistry combined with image
analysis (Figure 3
). When the
infectious titer was held below 4x109 pfu/mL,
neither ICAM-1 nor VCAM-1 showed significantly increased expression
above that observed in sham-infected arteries. However, as titers met
or exceeded that threshold, there was a steady increase in
endothelial expression of both adhesion molecules. We
observed a sigmoidal relationship between the log of infectious titer
used and relative staining intensity, with the steepest increase in
staining intensity occurring between 4x109 and
2x1010 pfu/mL.
|
We next compared the degree of inflammation in mock-infected vessels
and in low-titer (1.6x109 pfu/mL) and
moderate-titer (2x1010 pfu/mL)
adenovirus-infected arteries. Arteries were harvested 72 hours after
gene transfer, then cryosectioned, and (1) stained with X-Gal to
demonstrate ß-Galexpressing cells, followed by (2)
immunostaining for CD18 (Figure 4
, all panels). We observed the
following: (1) Mock-infected arteries showed no ß-Galpositive
nuclei (Figure 4A
), whereas arteries infected with moderate-titer
(Figure 4B
) and low-titer (Figure 4C
) adenovirus showed approximately
equal amounts of transduced endothelial cells (
80%
endothelial cell nuclei positive for ß-Gal). (2) In
mock-infected arteries (Figure 4A
) and low-titerinfected arteries
(Figure 4C
), endothelial inflammatory cells were
observed only occasionally. (3) In contrast, vessels infected with
moderate-titer adenovirus (Figure 4B
) showed extensive
endothelial infiltration by PMNs. Thus, low-titer and
moderate-titerinfected vessels differed primarily in the degree of
endothelial inflammatory cell infiltrate and were not
distinguishable in terms of transgene expression.
|
To quantify further the extent of inflammation, we counted
endothelium-adherent CD18+ and
CD43+ (pan T-lymphocyte) cells in cryosections
(Figure 5
). As was observed for
endothelial activation, the degree of inflammatory
infiltrate showed both time and titer dependence. A significant
inflammatory infiltrate developed as early as 6 hours after high-titer
adenovirus infection (1x1011 pfu/mL) and
progressed to near-maximal levels by 12 hours after gene transfer
(Figure 5
, left). Next, we examined the effect of viral titer on
inflammation at 72 hours after infection. At or below
1.6x109 pfu/mL, the number of
endothelial inflammatory cells was not increased
relative to mock-infected vessels (Figure 5
, right). However, at
4x109 pfu/mL, the inflammatory infiltrate
progressively increased. Numbers of PMNs continued to increase with
titers up to 5x1011 pfu/mL, whereas
CD43+ T lymphocytes were less numerous than PMNs
and did not show progressive increase with viral titer.
|
To determine whether ß-Gal transgene expression was contributing to
the observed inflammation, we infected 4 arteries with
5x1010 pfu/mL of an "empty vector"
(identical to Ad.ß-Gal but the ß-Gal transgene was absent) and 4
arteries with 5x1010 pfu/mL of Ad.ß-Gal and
compared the degree of adhesion molecule expression and inflammatory
cell infiltration between the 2 groups (Table 1
). Empty vector-infected
arteries and Ad.ß-Galinfected arteries were not distinguishable
with regard to any of the parameters studied, suggesting
that ß-Gal expression did not contribute significantly to the
observed inflammation.
|
Adenovirus-Mediated Vascular Gene Transfer Results in Functional
Endothelial Injury
To assess the functional impact of adenovirus-mediated gene
transfer, we excised rabbit carotid arteries 3 days after gene transfer
and evaluated their response to vasoactive agonists. Regardless of the
adenovirus titer received, all vessels showed essentially identical
contraction in response to PE (Figure 6A
). Similarly, all vessels relaxed in
response to treatment with the NO donor SNP (Figure 6C
). These
observations show that adenoviral gene transfer did not harm the
contraction and relaxation responses of vascular smooth muscle in the
medial layer. However, moderate- and high-titer gene transfer
significantly impaired endothelium-dependent relaxation
(Figure 6B
). Mock-infected arteries relaxed by up to 70% in response
to 10-5 mol/L ACh, as did arteries
infected with low-titer adenovirus (3x109
pfu/mL). In contrast, arteries infected with moderate- and high-titer
adenovirus (8x109 and
1x1011 pfu/mL, respectively) showed
progressively impaired relaxation responses to ACh (maximal relaxation,
50% and 30% of precontracted tension, respectively). An empty vector
(5x1010 pfu/mL) produced the same degree of
vasomotor impairment as did high-dose Ad.ß-Gal, showing that ß-Gal
expression itself did not cause the observed functional injury.
Arteries stripped of endothelium by balloon denudation
and then allowed to recover for 3 days showed minimal relaxation in
response to ACh. Relaxations to ACh were inhibited by
N-methyl-L-arginine, thus confirming their
dependence on NO production (data not shown).
|
We also evaluated the time course of vasomotor function at 6, 12, 24,
and 72 hours after infection with 1x1011 pfu/mL.
ACh-induced relaxation was significantly impaired as early as 6 hours
after infection, with further injury progressing through 72 hours
(Figure 7
). There was no significant
impact on either PE-induced contraction or SNP-induced relaxation at
any time after gene transfer (data not shown). Thus, adenovirus induces
time- and titer-dependent endothelial dysfunction but
does not impair vascular smooth muscle function.
|
Neutrophil Inflammation Mediates Functional Endothelial
Injury
We hypothesized that inflammatory cell infiltration may play a
role in the pathogenesis of adenovirus-related
endothelial injury. To investigate this possibility, we
induced neutropenia in rabbits undergoing carotid artery gene transfer.
Four rabbits received vinblastine (1.5 mg IV) on days 3 and 1 before
surgery. All animals survived until the designated time of harvest
without evidence of infection. At surgery, all vinblastine-treated
rabbits were profoundly neutropenic (15-fold reduction compared with
pretreatment) and remained so at the time of harvest (Table 2
). Peripheral
blood lymphocyte and platelet counts were modestly reduced at
surgery (2-fold and 2.5-fold, respectively), with further reductions
noted by the time of harvest.
|
Vinblastine pretreatment had no apparent effect on either VCAM-1 or
ICAM-1 expression after gene transfer; arteries from
vinblastine-treated animals still mounted a vigorous adhesion molecule
response after adenoviral gene transfer (Figure 8A
and 8B
; compare with Figure 2
at 24
hours). However, vinblastine pretreatment strikingly reduced
endothelial inflammatory cell infiltration (Figure 8C
and 8D
; compare with Figure 4B
). Endothelium-adherent
PMNs were reduced by 25-fold (Figure 9A
;
P<0.01), whereas endothelium-adherent
T-lymphocytes were reduced by 2-fold (P=NS) 3 days after
adenoviral gene transfer. Thus, vinblastine treatment did not affect
endothelial cell activation and only modestly reduced
T-lymphocyte infiltration but virtually abrogated
endothelial PMN infiltration in infected arteries.
|
|
We next sought to determine whether the marked reduction in endothelial PMNs favorably affected endothelial vasomotor function after adenoviral gene transfer. We examined vasomotor function in arteries from 4 groups of rabbits: (1) no vinblastine, mock-infected; (2) no vinblastine, high-titer gene transfer (1x1011 pfu/mL); (3) vinblastine-treated, mock- infected; and (4) vinblastine-treated, high titer gene transfer. Vinblastine treatment did not alter sensitivity to PE and modestly reduced sensitivity to SNP, reflecting a slight reduction in sensitivity to NO (for unknown reasons). Therefore, to standardize comparisons between vinblastine-treated and untreated animals, we expressed ACh-induced relaxation as a percentage of maximal SNP-induced relaxation. With this correction, ACh-induced relaxation was virtually identical in mock-infected arteries, regardless of vinblastine treatment.
We next compared ACh-induced relaxation in arteries from
untreated high-titer gene transfer rabbits with: (1) the contralateral
sham-infected carotid from the same animal and (2) arteries from
vinblastine, high-titer gene transfer rabbits (Figure 9B
). In untreated
rabbits, sham-infected arteries relaxed by >75% to ACh, whereas
high-titer adenovirus markedly impaired ACh-induced relaxation. But in
vinblastine-treated rabbits, ACh-induced relaxation was virtually
identical, regardless of whether the artery was mock-infected or
uninfected. Thus, high-titer adenovirus by itself did not impair
endothelial vasomotor function, if the rabbit was first
made neutropenic with vinblastine. It is host-mediated inflammation,
rather than direct effects of the virus, that induces the observed
deficit in endothelial vasomotor function.
| Discussion |
|---|
|
|
|---|
The precise boundaries of the therapeutic window will be affected by a number of variables. For example, our boundaries apply to rabbit carotids exposed to virus for 15 minutes, but they may be quite different, for example, for other species, shorter or longer exposures, and different organ systems. Moreover, the titer determinations themselves may vary considerably between laboratories. Thus, therapeutic window boundaries must be determined on a case-by-case basis.
We show that adenovirus-induced inflammation is well developed as early as 6 hours after vascular gene transfer. This onset is too soon to attribute to 2 key adenovirus life cycle events: adenoviral viral DNA replication and late antigen expression.21 This has important implications for vascular gene transfer with newer adenoviral vectors, which are designed to reduce or eliminate viral replication and antigen expression.22 23 Our data suggest that acute vascular injury may be primarily determined by events surrounding the infection itself. If so, second-generation vectors will continue to induce titer-dependent acute inflammation, and strict attention to the therapeutic window will continue to be important.
Reduced ACh-induced vascular relaxation reflects loss of endothelial NO production,24 and that, in turn, may facilitate the long-term chronic inflammation and vascular injury that is known to occur in this model.7 NO and related molecules reduce the expression of adhesion molecules and proinflammatory cytokines,25 26 inhibit platelet aggregation and adhesion,27 28 and directly inhibit vascular smooth muscle cell proliferation29 and migration.30 Thus, the detrimental effects of early endothelial injury may extend beyond acute loss of ACh-induced relaxation and may contribute to the long-term vascular injury induced by recombinant adenovirus.
The observed vasomotor impairment has a number of striking parallels to the inflammatory cell infiltrate in terms of temporal development, dependence on titer, and spatial distribution (ie, both inflammation and vasomotor impairment affect the endothelium and spare the vascular media). These tight parallels suggest the possibility of a causal relationship. Our results with cytopenic animals further support this hypothesis: vinblastine-induced cytopenia (1) virtually eliminated endothelial cellular infiltration and (2) prevented the loss of ACh-induced vascular relaxation that otherwise occurs after exposure to high-titer adenovirus. Moreover, it is noteworthy that vinblastine treatment had no discernible effect on endothelial ICAM-1 or VCAM-1 expression. This result shows that vasomotor impairment requires additional events beyond those necessary for endothelial activation. Again, this would implicate cellular infiltration as playing a causal role.
Our observations regarding vasomotor function contrast sharply with those of Lafont et al.10 They described complete loss of endothelium-dependent relaxation and substantial loss of PE-induced contraction in rabbit ear and femoral arteries 3 days after adenoviral gene transfer at 4x1010 pfu/mL. In contrast, our carotid artery data suggest that adenoviral gene transfer does not affect vascular smooth muscle function at any titer and does not harm endothelial function if one uses titers within the therapeutic window. Finally, our data show that vasomotor dysfunction induced by high-titer adenovirus can be prevented by prior treatment with vinblastine.
Vinblastine treatment induced neutropenia, lymphopenia, and
thrombocytopenia. Any of these cytopenias may play an important role in
reducing endothelial injury after gene transfer. The
fact that PMNs were the most affected by vinblastine treatment, both in
terms of reduced peripheral counts and reduced
endothelial infiltration, suggests that neutrophils
have the most significant role. Certainly, their ability to release
proinflammatory mediators (eg, superoxide, tumor necrosis factor-
,
and interleukin-1ß31) and to generate tissue
injury lends support for this view. However, a more targeted
experimental approach is necessary to establish definitively whether
PMNs are the agents of functional endothelial injury in
this model.
Important questions remain to be answered about the pathogenesis of acute effects. What aspects of recombinant adenovirus infection trigger endothelial activation? Does the initial infection represent the sole stimulus for subsequent inflammatory events, or do viral DNA replication or protein expression contribute to the progression of injury observed from 12 to 72 hours? We show that neutrophils may mediate endothelial injury, but through what mechanisms are the neutrophils recruited and activated? Vascular selectins, C5a, interleukin-8, and platelet-activating factor all mediate acute inflammation in other models,32 33 34 35 and recent studies show that wild-type and recombinant adenoviruses rapidly upregulate interleukin-8 expression in cultured cells.36 37 Any of these mediators may be involved in adenovirus-induced acute inflammation in vivo. Clarification of these mechanisms may have important implications for vascular gene therapy.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received March 4, 1998; accepted March 30, 1998.
| References |
|---|
|
|
|---|
2.
Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ,
Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular
proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science. 1995;267:518522.
3. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293298.[Medline] [Order article via Infotrieve]
4.
Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E,
Wilson JM. Cellular immunity to viral antigens limits E1-deleted
adenoviruses for gene therapy. Proc Natl Acad Sci U S A.. 1994;91:44074411.
5.
Dai Y, Schwarz EM, Gu D, Zhang W, Sarvetnick N, Verma
IM. Cellular and humoral immune responses to adenoviral vectors
containing factor IX gene: tolerization of factor IX and vector
antigens allows for long-term expression. Proc Natl Acad Sci
U S A.. 1995;92:14011405.
6.
French BA, Mazur W, Ali NM, Geske RS, Finnigan JP,
Rodgers GP, Roberts R, Raizner AE. Percutaneous
transluminal in vivo gene transfer by recombinant adenovirus in normal
porcine coronary arteries, atherosclerotic arteries, and two
models of coronary restenosis. Circulation. 1994;90:24022413.
7. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:29552965.
8.
Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA.
Endothelium-specific in vivo gene transfer. Circ
Res. 1995;77:475485.
9.
Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo
gene transfer into injured carotid arteries: optimization and
evaluation of acute toxicity. Circulation. 1995;91:24072414.
10. Lafont A, Loirand G, Pacaud P, Vilde F, Lemarchand P, Escande D. Vasomotor dysfunction early after exposure of normal rabbit arteries to an adenoviral vector. Hum Gene Ther. 1997;8:10331040.[Medline] [Order article via Infotrieve]
11. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 1993;4:403409.[Medline] [Order article via Infotrieve]
12. Pereria HG. A protein factor responsible for the early cytopathic effect of adenoviruses. Virology. 1958;6:601611.[Medline] [Order article via Infotrieve]
13. Valentine RC, Pereira HG. Antigens and the structure of adenovirus. J Mol Biol. 1965;13:1320.[Medline] [Order article via Infotrieve]
14. Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther. 1994;5:731744.[Medline] [Order article via Infotrieve]
15. Channon KM, Blazing MA, Shetty GA, Potts KE, George SE. Adenoviral gene transfer of nitric oxide synthase: high level expression in human vascular cells. Cardiovasc Res. 1996;32:962972.[Medline] [Order article via Infotrieve]
16. Graham FL, Prevec L. Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols. Clifton, NJ: Humana Press Inc; 1991:109.
17. Rosenshein MS, Price TH, Dale DC. Neutropenia, inflammation, and the kinetics of transfused neutrophils in rabbits. J Clin Invest. 1979;64:580585.
18. Langdale LA, Flaherty LC, Liggitt HD, Harlan JM, Rice CL, Winn RK. Neutrophils contribute to hepatic ischemia-reperfusion injury by a CD18-independent mechanism. J Leukoc Biol. 1993;53:511517.[Abstract]
19. Galea-Lauri J, Blackford J, Wilkinson JM. The expression of CD11/CD18 molecules on rabbit leukocytes: identification of monoclonal antibodies to CD18 and their effect on cellular adhesion processes. Mol Immunol. 1993;30:529537.[Medline] [Order article via Infotrieve]
20.
Tanaka H, Sukhova GK, Swanson SJ, Glinton SK, Ganz P,
Cybulsky M, Libby P. Sustained activation of vascular cells and
leukocytes in the rabbit aorta after balloon injury.
Circulation. 1993;88:17881803.
21. Horwitz MS. Adenoviridae and their replication. In: Fields BN, Knipe DM, ed. Virology. New York, NY: Raven Press Publishers; 1990:16791721.
22.
Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of
E2A in recombinant adenoviruses improves transgene persistence and
decreases inflammatory response in mouse liver. Proc Natl Acad
Sci U S A.. 1994;91:61966200.
23. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 1995;2:775783.[Medline] [Order article via Infotrieve]
24.
Rees DD, Palmer RM, Moncada S. Role of
endothelium-derived nitric oxide in the regulation of
blood pressure. Proc Natl Acad Sci U S A.. 1989;86:33753378.
25.
Niu X, Smith CW, Kubes P. Intracellular oxidative
stress induced by nitric oxide synthesis inhibition increases
endothelial cell adhesion to neutrophils. Circ
Res. 1994;74:11331140.
26. De Caterina R, Libby P, Peng H-B, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:6068.
27. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148:14821489.[Medline] [Order article via Infotrieve]
28.
Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric
oxide pathway present in human platelets regulates aggregation.
Proc Natl Acad Sci U S A.. 1990;87:51935197.
29. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:17741777.
30.
Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC.
Nitric oxide reversibly inhibits the migration of cultured vascular
smooth muscle cells. Circ Res. 1996;78:225230.
31. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol. 1993;33:7190.[Medline] [Order article via Infotrieve]
32. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990;343:757760.[Medline] [Order article via Infotrieve]
33. Lorant DE, Topham MK, Whatley RE, McEver RP, McIntyre TM, Prescott SM, Zimmerman GA. Inflammatory roles of P-selectin. J Clin Invest. 1993;92:559570.
34. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:11471155.
35. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit: evidence for a role for C5a and interleukin-8 [comment]. J Clin Invest. 1995;95:27202728.
36. Amin R, Wilmott R, Schwarz Y, Trapnell B, Stark J. Replication-deficient adenovirus induces expression of interleukin-8 by airway epithelial cells in vitro. Hum Gene Ther. 1995;6:145153.[Medline] [Order article via Infotrieve]
37. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol. 1997;71:398404.[Abstract]
This article has been cited by other articles:
![]() |
T. Murata, M. Hori, S. Lee, A. Nakamura, K. Kohama, H. Karaki, and H. Ozaki Vascular Endothelium Has a Local Anti-Adenovirus Vector System and Glucocorticoid Optimizes Its Gene Transduction Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1796 - 1803. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1761 - 1774. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, T. Ha, X. Gao, J. Kelley, D. L. Williams, I. W. Browder, R. L. Kao, and C. Li NF-{kappa}B activation is required for the development of cardiac hypertrophy in vivo Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1712 - H1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wen, S. Graf, P. G. Massey, and D. A. Dichek Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral Vector Circulation, September 14, 2004; 110(11): 1484 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Kopp, T. Holzenbein, S. Steiner, R. Marculescu, H. Bergmeister, D. Seidinger, I. Mosberger, C. Kaun, M. Cejna, R. Horvat, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity Blood, March 1, 2004; 103(5): 1653 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Chiu-Pinheiro, T. O'Brien, Z. S. Katusic, L. F. Bonilla, C. E. Hamner, and H. V. Schaff Gene transfer to coronary artery bypass conduits Ann. Thorac. Surg., October 1, 2002; 74(4): 1161 - 1166. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Scherpereel, J. J. Rome, R. Wiewrodt, S. C. Watkins, D. W. Harshaw, S. Alder, M. Christofidou-Solomidou, E. Haut, J.-C. Murciano, M. Nakada, et al. Platelet-Endothelial Cell Adhesion Molecule-1-Directed Immunotargeting to Cardiopulmonary Vasculature J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 777 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-F. Li, S. K. Roy, K. M. Channon, I. H. Zucker, and K. P. Patel Effect of in vivo gene transfer of nNOS in the PVN on renal nerve discharge in rats Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H594 - H601. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wen, R. M. Driscoll, D. B. Schneider, and D. A. Dichek Inclusion of the E3 Region in an Adenoviral Vector Decreases Inflammation and Neointima Formation After Arterial Gene Transfer Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1777 - 1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stenvinkel Endothelial dysfunction and inflammation--is there a link? Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1968 - 1971. [Full Text] [PDF] |
||||
![]() |
S. J. White, S. A. Nicklin, T. Sawamura, and A. H. Baker Identification of Peptides That Target the Endothelial Cell-Specific LOX-1 Receptor Hypertension, February 1, 2001; 37(2): 449 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Atsuchi, T. Nishida, K. Marutsuka, Y. Asada, Y. Kamikubo, A. Takeshita, and H. Ueno Combination of a Brief Irrigation With Tissue Factor Pathway Inhibitor (TFPI) and Adenovirus-Mediated Local TFPI Gene Transfer Additively Reduces Neointima Formation in Balloon-Injured Rabbit Carotid Arteries Circulation, January 30, 2001; 103(4): 570 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gallo-Penn, P. S. Shirley, J. L. Andrews, S. Tinlin, S. Webster, C. Cameron, C. Hough, C. Notley, D. Lillicrap, M. Kaleko, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs Blood, January 1, 2001; 97(1): 107 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wen, D. B. Schneider, R. M. Driscoll, G. Vassalli, A. B. Sassani, and D. A. Dichek Second-Generation Adenoviral Vectors Do Not Prevent Rapid Loss of Transgene Expression and Vector DNA From the Arterial Wall Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1452 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.’i. Sato, T. Mohacsi, A. Noel, C. Jost, P. Gloviczki, G. Mozes, Z. S. Katusic, T. O’Brien, and W. G. Mayhan In Vivo Gene Transfer of Endothelial Nitric Oxide Synthase to Carotid Arteries From Hypercholesterolemic Rabbits Enhances Endothelium-Dependent Relaxations • Editorial Comment Stroke, April 1, 2000; 31(4): 968 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.Y. Alexander, M.J. Brosnan, C. A Hamilton, P. Downie, A. M Devlin, F. Dowell, W. Martin, H. M Prentice, T. O'Brien, and A. F Dominiczak Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model Cardiovasc Res, August 15, 1999; 43(3): 798 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishida, H. Ueno, N. Atsuchi, R. Kawano, Y. Asada, Y. Nakahara, Y.-i. Kamikubo, A. Takeshita, and H. Yasui Adenovirus-Mediated Local Expression of Human Tissue Factor Pathway Inhibitor Eliminates Shear Stress–Induced Recurrent Thrombosis in the Injured Carotid Artery of the Rabbit Circ. Res., June 25, 1999; 84(12): 1446 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qian, V. Neplioueva, G. A. Shetty, K. M. Channon, and S. E. George Nitric Oxide Synthase Gene Therapy Rapidly Reduces Adhesion Molecule Expression and Inflammatory Cell Infiltration in Carotid Arteries of Cholesterol-Fed Rabbits Circulation, June 15, 1999; 99(23): 2979 - 2982. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Luo, M. Sata, T. Nguyen, J. M. Kaplan, G. Y. Akita, and K. Walsh Adenovirus-Mediated Delivery of Fas Ligand Inhibits Intimal Hyperplasia After Balloon Injury in Immunologically Primed Animals Circulation, April 13, 1999; 99(14): 1776 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Erl, G. K. Hansson, R. de Martin, G. Draude, K. S. C. Weber, and C. Weber Nuclear Factor-{kappa}B Regulates Induction of Apoptosis and Inhibitor of Apoptosis Protein-1 Expression in Vascular Smooth Muscle Cells Circ. Res., April 2, 1999; 84(6): 668 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Channon, H. Qian, V. Neplioueva, M. A. Blazing, E. Olmez, G. A. Shetty, S. A. Youngblood, J. Pawloski, T. McMahon, J. S. Stamler, et al. In Vivo Gene Transfer of Nitric Oxide Synthase Enhances Vasomotor Function in Carotid Arteries From Normal and Cholesterol-Fed Rabbits Circulation, November 3, 1998; 98(18): 1905 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Morishita Lessons From Human Arteries : How to Design a Gene Therapy Strategy for Treatment of Cardiovascular Disease Circ. Res., June 29, 1998; 82(12): 1349 - 1351. [Full Text] [PDF] |
||||
![]() |
H. S. Qian, K. Channon, V. Neplioueva, Q. Wang, M. Finer, L. Tsui, S. E. George, and J. McArthur Improved Adenoviral Vector for Vascular Gene Therapy : Beneficial Effects on Vascular Function and Inflammation Circ. Res., May 11, 2001; 88(9): 911 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Tsui, A. Camrud, J. Mondesire, P. Carlson, N. Zayek, L. Camrud, B. Donahue, S. Bauer, A. Lin, D. Frey, et al. p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion Circ. Res., August 17, 2001; 89(4): 323 - 328. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |